Recent work published in Geroscience highlights an unexpected connection between topoisomerase inhibitors and longevity biology.

Using a transcriptomics-driven discovery platform, researchers identified topoisomerase drugs (like amonafide) are a novel class of geroprotective agents. In C. elegans, these compounds improved mobility during aging and extended lifespan by activating conserved stress-response pathways, including the mitochondrial unfolded protein response (UPRmt).

This is a striking shift in perspective: topoisomerase inhibitors traditionally viewed through an oncology lens (e.g., Top2 poisons) may also modulate fundamental aging pathways linked to genome stability, mitochondrial signaling, and cellular defense programs!

For those working at the interface of DNA topology, genome maintenance, and translational aging research, this opens many compelling opportunities & TopoGEN is uniquely positioned to enable and accelerate this line of investigation.

Our portfolio of highly purified human topoisomerases (Top1, Top2α/β), DNA substrates (including kDNA), and mechanistic assay platforms (relaxation, decatenation, and ICE assays) allows researchers to:
• Dissect **Top2-dependent vs. off-target drug mechanisms**
• Quantify cleavage complex formation in cells (critical for “poison” vs. catalytic inhibitor classification)
• Translate in vivo findings into **human-relevant biochemical and cellular systems**
• Rapidly screen next-generation compounds for **geroprotective vs. genotoxic profiles**
As the field moves from worm models toward human systems, **mechanistic clarity will be the gating factor**—and that is precisely where TopoGEN delivers.
If you are exploring topoisomerases in aging, neurodegeneration, or genome stability, we welcome the opportunity to collaborate.

#AgingResearch #LongevityScience #HealthyAging #DrugDiscovery #TopoGENCRO #TopoAssays #topoinhibitors